CURRICULUM VITAE
PERSONAL INFORMATION
Name: Michael E. Jung
Date and Place of Birth: May 14, 1947 in New Orleans, Louisiana
Marital Status: Married, wife Alice
Mailing Address: Department of Chemistry
University of California
Los Angeles, CA 90095-1569
Telephone: (310) 825-7954 FAX: (310) 206-3722
email: jung@chem.ucla.edu
EDUCATIONAL BACKGROUND
Walter and Shirley Wang Chair in Medicinal Drug Discovery, UCLA, 2021 - present
University of California Presidential Chair in Medicinal Chemistry, UCLA, 2018 - 2021
Distinguished Professor Further Above Scale (3 times), UCLA, 2018 - present
Distinguished Professor Further Above Scale, UCLA, 2010 - 2018
Distinguished Professor, UCLA, 2004 - 2010
Professor Further Above Scale, UCLA, 2002 - 2004
Professor Above Scale, UCLA, 1998 - 2002
Professor VIII, UCLA, 1996 - 1998
Professor VII, UCLA, 1994 - 1996
Professor VI, UCLA, 1992 - 1994
Professor V, UCLA, 1990 - 1992
Professor IV, UCLA, 1988 - 1990
Professor III, UCLA, 1987 - 1988
Professor II, UCLA, 1985 - 1987
Professor I, UCLA, 1983 - 1985
Associate Professor III, UCLA, 1981 - 1983
Associate Professor I, UCLA, 1979 - 1981
Assistant Professor IV, UCLA, 1977 - 1979
Assistant Professor III, UCLA, 1976 - 1977
Assistant Professor II, UCLA, 1974 - 1976
NATO Postdoctoral Fellowship, Eidgenössische Technische Hochschule, Zürich, Switzerland, 1973 - 1974; Albert Eschenmoser, advisor
Ph.D., Columbia University, New York, New York, 1973; Gilbert Stork, advisor
B.A., Summa cum laude, Rice University, Houston, Texas, 1969; Richard Turner, advisor
PROFESSIONAL AFFILIATION
American Chemical Society, 1969 - present
The Chemical Society, 1971 - present
Phi Lambda Upsilon, 1968 - present
UCLA Cancer Center, 1975 - present
Division of Organic Chemistry, ACS, 1975 - present
Division of Medicinal Chemistry, ACS, 1975 - present
Sigma Xi, 1977 - present
American Men and Women of Science, Chemistry, 1977 - present
American Association for the Advancement of Science, 1979 - present
Molecular Biology Institute, UCLA, 2004 - present
California
NanoSystems Institute (CNSI), UCLA, 2006 - present.
Director, UCLA Biosciences Synthetic Chemistry Core Facility, 2006 - present.
UCLA Medical School, Department of Molecular and Medical Pharmacology (Joint Appointment), 2014 - present.
National Academy of Inventors, 2015 - present.
Associate Dean for Entrepreneurship and Innovation, Division of Physical Sciences, UCLA, 2016 - present.
UCLA CNSI Magnify Incubator Selection Committee, UCLA, 2018 - present.
Visiting Investigator, The Scripps Research Institute, 2019 - present.
COWORKERS
Current:
9 postdoctoral associates
Former: 95 PhD's granted, 9 MS's granted, 140 former postdoctoral associates, 47 undergraduates, 21 research associates and technicians
HONORS AND AWARDS
Professional - University of California
|
2024 |
Induction into the American Chemical Society Medicinal Chemistry Division Hall of Fame, ACS meeting, Denver, CO |
|
|
2024 |
Plenary Speaker, ACS Ronald Breslow Award Symposium, New Orleans, LA |
|
|
2024 |
Plenary Speaker, 24th Annual R. Bryan Miller Symposium, UC Davis |
|
|
2024 |
Plenary Speaker, 35th Annual Frontiers in Chemistry Symposium, Scripps, La Jolla, CA |
|
|
2023 |
Plenary Speaker, Annual Meeting of the Tübingen Medicinal Chemistry School, Tübingen, Germany |
|
|
2023 |
Plenary Speaker, Annual Meeting of the German Pharmaceutical Society, Tübingen, Germany |
|
|
2022 |
International Union of Pure and Applied Chemistry (IUPAC)-Richter Prize in Medicinal Chemistry |
|
|
2021 |
Walter and Shirley Wang Chair in Medicinal Drug Discovery, UCLA |
|
|
2021 |
UCLA Faculty Research Lecturer |
|
|
2019 |
After Dinner Speaker, UCLA Biomedical and Life Science Innovation Day |
|
|
2019 |
American Association for Cancer Research Award for Outstanding Achievement in Chemistry in Cancer Research |
|
|
2019 |
Alexander Cruickshank Memorial Lecturer, University of Rhode Island |
|
|
2019 |
Keynote Lecturer, UCLA Brain Research Center, NIH SPORE meeting, UCLA |
|
|
2018 |
University of California Presidential Chair in Medicinal Chemistry, UCLA |
|
|
2018 |
Invited Lecture, Amgen Inventors' Banquet, Ronald Reagan Presidential Library, Simi Valley, CA |
|
|
2018 |
Invited Lecture, Gilbert Stork Memorial Symposium, Columbia University, New York, NY |
|
|
2018 |
Keynote Lecture, UCLA Biomedical/Life Science Innovation Day, University of California, Los Angeles, CA |
|
|
2017 |
The Inaugural Nguyen and Tarbet Seminar in Translational Research, University of California, Irvine, CA |
|
|
2017 |
Plenary Lecturer, The William S. Johnson Symposium, Stanford, CA |
|
|
2017 |
The Inaugural Pfizer Oncology Lecture in Medicinal Chemistry, the Scripps Research Institute, La Jolla, CA |
|
|
2017 |
Plenary Lecturer, American Chemical Society Medicinal Chemistry Division and European Federation for Medicinal Chemistry Symposium, Philadelphia |
|
|
2017 |
Plenary Lecturer, 9th CINVESTAV/Sigma-Merck Symposium, Mexico City, Mexico |
|
|
2017 |
Plenary Lecturer, 2017 Sigma Aldrich Symposium, University of Texas Southwestern Medical Center, Dallas, TX |
|
|
2016 |
Glenn T. Seaborg Award Medalist, UCLA |
|
|
2016 |
Keynote Speaker, Yao Yuan Symposium, Chicago, IL |
|
|
2016 |
Richard C. Tolman Award, Southern California Section of the American Chemical Society |
|
|
2016 |
Carl M. Franklin Lecturer, University of Southern California |
|
|
2015 |
American Association of Cancer Research Team Science Award |
|
|
2015 |
National Academy of Inventors Inductee |
|
|
2012 |
Keynote Speaker, UCLA Department of Pharmacology Annual Retreat |
|
|
2011 |
Visiting Professor, Université Pierre et Marie Curie, Paris, France |
|
|
2011 |
Plenary Lecturer, Groupe Etude Chimie Organique Symposium, Aber Wrac'h, France |
|
|
2011 |
Plenary Lecturer, First Mexican Meeting on Pure and Applied Chemistry, Mexico City |
|
|
2011 |
Plenary Lecturer, USC Stauffer Symposium, Los Angeles, CA |
|
|
2011 |
Plenary Lecturer, ACS Award Symposium Award in Industrial Chemistry, Anaheim, CA |
|
|
2010 |
Plenary Lecturer, 14th International Congress on Hormonal Steroids, and Hormones and Cancer, Edinburgh |
|
|
2010 |
Dr. Paul Janssen Lecture Series in Organic Chemistry Lecturer, Johnson & Johnson Pharmaceeutical R&D, Beerse, Belgium |
|
|
2009 |
Herbert Newby McCoy Award Recipient, UCLA | |
|
2009 |
Plenary Lecturer, ZaCh Systems Symposium on Organic Synthesis, Paris |
|
2009 |
Plenary Lecturer, Center for Cancer Research Eminent Lecture Series, National Cancer |
|
|
2008 |
Organic Synthesis Symposium, 43rd Mexican Chemical Society National Meeting, Tijuana, Mexico | |
|
2008 |
Plenary Lecturer, Symposium in honor of Victor Marquez, American Chemical Society National Meeting, Philadelphia, PA |
|
|
2008 |
Plenary Lecturer, Chemical Insights into Biological Processes, Center for Cancer Research, National Cancer Institute, Frederick, MD |
|
|
2008 |
Plenary Lecturer, Symposium on Organic Synthesis, 91st National Meeting of the Canadian Society for Chemistry, Edmonton, Canada |
|
|
2007 |
Wolfrom Award Symposium in honor of Muthiah Manoharan, 234th ACS National Meeting, Boston, MA |
|
|
2006 |
Boehringer-Ingelheim Lecturer, University of British Columbia, Vancouver |
|
|
2004 |
Plenary Lecturer, Ischia Advanced School of Organic Chemistry, Ischia, Italy |
|
|
2004 |
Bristol-Myers Squibb Lecturer, University of Puerto Rico, Rio Piedras, PR |
|
|
2003 |
Invited Professor, Université Pierre et Marie Curie, Paris |
|
|
2002 |
Auspex Horizon Award, Auspex Pharmaceutical Co., Inc., San Diego, CA |
|
|
2002 |
Plenary Lecturer, 60th Anniversary International Symposium on Organic Synthesis, Tokyo, Japan |
|
|
2001 |
Plenary Lecturer, First International Symposium on Asymmetric Synthesis, Universidad Nacional Autonoma de Mexico (UNAM), Mexico City |
|
|
1999 |
Plenary Lecturer, Japan Pharmaceutical Society, Tokushima, Japan |
|
|
1999 |
Plenary Lecturer, Japan Chemical Society, Tokyo, Japan |
|
|
1998 |
Plenary Lecturer, 21st Gulf Coast Chemistry Conference, Pensacola, FL |
|
|
1998 |
Invited Lecturer, XIII International Round Table on Nucleosides, Nucleotides and Their Biological Applications, Montpellier, France |
|
|
1998 |
Invited Lecturer, 19th International Carbohydrate Symposium, La Jolla, CA |
|
|
1998 |
Plenary Lecturer, Western Switzerland Lecture Tour |
|
|
1998 |
Plenary Speaker, Spring Meeting, French Chemical Society, Paris |
|
|
1998 |
Plenary Lecturer, Robert A. Welch Foundation |
|
|
1997 |
Plenary Speaker, 2nd AFMC International Medicinal Chemistry Symposium (AIMECS 97), Seoul |
|
|
1997 |
Invited Lecturer, 16th International Congress of Heterocyclic Chemistry, Montana State University, Bozeman, MT |
|
|
1995 |
American Chemical Society Arthur C. Cope Scholar Award |
|
|
1995 |
Plenary Lecturer, Gordon Conference on Purines, Pyrimidines, and Other Related Substances |
|
|
1995 |
Plenary Lecturer, 5th French American Chemical Society (FACS) Conference |
|
|
1992 |
Hanson-Dow Teaching Award, UCLA |
|
|
1991 |
Herbert Newby McCoy Award Recipient, UCLA |
|
|
1991 |
Fujii-Ohtsuka Professor, University of Tokushima, Tokushima, Japan |
|
|
1988 |
Plenary Lecturer, 3rd Nozaki Conference, Sagamihara, Japan |
|
|
1987 |
Glenn T. Seaborg Award Recipient |
|
|
1987 |
Plenary Lecturer, Gordon Conference on Natural Products Chemistry |
|
|
1987 |
Plenary Lecturer, Gordon Conference on Organic Reactions and Processes |
|
|
1986 |
Inaugural UCLA Gold Shield Faculty Prize |
|
|
1985 |
Plenary Lecturer, 9th Oxford Symposium on Organic Synthesis, Oxford |
|
|
1982 |
Plenary Lecturer, 4th International Conference on Organic Synthesis, Tokyo |
|
|
1981 |
Invited Participant, Twelfth Annual Workshop on Organic Synthesis in Natural Products Chemistry, Pingree Park, Colorado |
|
|
1981 |
Plenary Lecturer, French Chemical Society Meeting, Paris (Spring) |
|
|
1980 |
Fulbright-Hays Grant, U.S. Research Scholar Award |
|
|
1980 |
American Cyanamid Young Researcher Award |
|
|
1980 |
Plenary Lecturer, Gordon Conference on Organometallic Chemistry |
|
|
1979 |
Alfred P. Sloan Foundation Research Fellow |
|
|
1979 |
Camille and Henry Dreyfus Teacher-Scholar Grantee |
|
|
1977 |
Eli Lilly Grantee |
|
|
1978 |
University Distinguished Teaching Award |
|
|
1978 |
Invited Speaker, Symposium for Creative Work in Synthetic Organic Chemistry, 175th ACS National Meeting, Anaheim |
|
|
1978 |
Plenary Lecturer, 5th Annual Conference on Organosilicon Chemistry |
|
|
1977 |
Invited Participant, Eight Annual Workshop on Organic Synthesis in Natural Products Chemistry, Dartmouth College Minary Conference Center, NH |
|
|
1975 |
UCLA Summer Faculty Fellow |
Postgraduate
- Eidgenössische Technische
Hochschule
1973 NATO
Postdoctoral Fellow
1973
Hammett
Award for Research 1969-73
National
Science Foundation Predoctoral Fellow Undergraduate
- Rice University 1968
Phi Beta Kappa 1967-69
ARCS
Foundation Scholar 1967-68
Blanche
White Honor Scholar 1966-67
William
Marsh Rice Scholar 1965-66
University
Prize Scholar
FOUNDER
WZJ Therapeutics, Inc., Los Angeles, CA, 2023 - present
Sardona, Inc., Los Angeles, CA, 2020 - present
Katmai Pharmaceuticals, Inc., Los Angeles, CA, 2019 - present
Athos Therapeutics, Inc., Los Angeles, CA, 2019 - present
Pelage Pharmaceutical, Inc., Los Angeles, CA, 2018 - present
Enspire Bio, Inc., Los Angeles, CA, 2017 - present
LongLifeRx, Inc., Los Angeles, CA, 2014 - present
Trethera, Inc., Los Angeles, CA, 2013 - present
MAX BioPharma, Inc., Los Angeles, CA, 2011 - present
WZJ Therapeutics, Inc., Los Angeles, CA, 2018 - 2021
Aravalent, Inc., Los Angeles, CA, 2020 - 2021
Westwood Therapeutics, Los Angeles, CA, 2020 - 2022
Enlibrium, Inc., La Jolla, CA, 2015 - 2018
Eutropix, Inc., Los Angeles, CA, 2012 - 2013
Aragon Pharmaceuticals, Inc., La Jolla, CA, 2009 - 2013
MEMBER, BOARD OF DIRECTORS LongLifeRx, Inc., Los Angeles, CA, 2014 - 2023 WZJ Therapeutics, Inc., Los Angeles, CA, 2018 - 2021
MEMBER, SCIENTIFIC ADVISORY BOARD WZJ Therapeutics, Inc., Los Angeles, CA, 2023 - present Sardona, Inc., Los Angeles, CA, 2020 - present Katmai Pharmaceuticals, Inc., Los Angeles, CA, 2019 - present Athos Therapeutics, Inc., Los Angeles, CA, 2019 - present Pelage Pharmaceutical, Inc., Los Angeles, CA, 2018 - present PMV Pharma, Philadelphia, PA, 2016 - present LongLifeRx, Inc., Los Angeles, CA, 2014 - 2023 Aravalent, Inc., Los Angeles, CA, 2020 - 2021 Westwood Therapeutics, Los Angeles, CA, 2020 - 2022 WZJ Therapeutics, Inc., Los Angeles, CA, 2018 - 2021 Enlibrium, Inc., La Jolla, CA, 2015 - 2018 Auspex Pharmaceuticals, Inc., Vista, CA, 2004 - 2012 Medivation, Inc., San Francisco, CA, 2006 - 2009 Encore Pharmaceutical, Inc., Loma Linda, CA, 1998 - 2002
CONSULTANTSHIPS
Gilead Science Process Chemistry, Foster City, CA, 1996 - present
Gilead Science Medicinal Chemistry, Foster City, CA, 1999 - present
PMV Pharma, Doylestown, PA, 2014 - present WZJ Therapeutics, Inc., Los Angeles, CA, 2023 - present
FORMER CONSULTANTSHIPS
Institut de Recherche Servier, Servier Pharmaceutical Inc., Suresnes, France, 2000 - 2022
Pfizer, Inc., San Diego, CA, 2011 - 2020
DuPont Crop Protection, Newark, DE, 2002 - 2019
Alnylam, Inc., Cambridge, MA, CA, 2003 - 2019
Prestwick Chemicals, Inc., Strasbourg, France 2007 - 2018
Crestone Pharma, Denver, CO, 2012 - 2018
ORIL, S.A., Bolbec, France, 1996 - 2016
The majority of the research personnel in my group are currently engaged in two
general fields of interest: the development of new synthetic methods for the total
synthesis of biologically active natural products and synthetic medicinal chemistry.
We are pursuing the use of new methods for the total synthesis of several molecules
with promising biological activity, e.g., parthenolide, rugulosone, and gymnostatin G.
We have several collaborative programs in medicinal chemistry, e.g.: a) the preparation
and testing of novel small molecule androgen receptor antagonists which inhibit the
growth of castration-resistant prostate cancer; b) the preparation of analogues of
metformin that show great promise as antitumor agents; c) the preparation and testing
of new selective binders for the estrogen receptor as potential anti-breast cancer agents
and agents to treat multiple sclerosis; d) the preparation of analogues of parthenolide
which have been shown to kill cancer stem cells; e) the development of inhibitors of
deoxycytidine kinase for the treatment of leukemia; f) the synthesis of small molecules,
e.g., esters of alpha-ketoglutarate, which extend the life span of animals via a novel
mechanism; g) the preparation of small molecules which differentiate stem cells into
osteoblasts for bone growth; h) the design and preparation of small molecule inhibitors
of the growth of many enveloped viruses and also specifically for enteroviruses; i) the
design and preparation of small molecule inhibitors of protein tyrosine phosphatase-sigma
(PTP-sigma) as agents to increase stem cell production; j) the design and synthesis of
novel small molecule radiomitigators; k) the development of small 'read-through'
molecules which allow the production of full-length dystrophin for the treatment of
muscular dystrophy; l) the preparation and testing of small molecule which upregulate
the production of Sirt1 for the treatment of Alzheimer's disease; m) the preparation
of molecules that bind to the Sortase-A binding pocket as potential antibacterial
agents; n) small molecules which activate NPEPPS and destroy tau and phospho-tau for
the treatment of Alzheimers Disease; o) small molecule inhibitors of ENPP1, a phosphatase
that is important in ectopic calcification; and p) small molecule that inhibit the
activity of the ASTER group of protein for cholesterol trafficking and homeostasis.
1.
M. E. Jung, "An Improved Procedure for the Conversion of
Amines to
Alcohols at Low Temperature; New Synthesis of Alkenes and Alkynes from
Amines,"
Chemtracts 1990,
3, 392. 2.
M. E. Jung, "Iodomethyl Methyl Ether," Encyclopedia
of Reagents for
Organic Synthesis, John Wiley
& Sons,
Ltd., 1995. 3.
M. E. Jung, "Trimethylsilyl iodide," Encyclopedia
of Reagents for
Organic Synthesis, John Wiley
& Sons,
Ltd., 1995. 4.
M. E. Jung, "1-Trimethylsilyloxy-1,3-butadiene," Encyclopedia
of
Reagents for Organic Synthesis,
John Wiley
& Sons, Ltd., 1995. 5.
M. E. Jung, "2-Trimethylsilyloxy-1,3-butadiene," Encyclopedia
of
Reagents for Organic Synthesis,
John Wiley
& Sons, Ltd., 1995. 6.
M. E. Jung, "Triphenylcarbenium
Tetrafluoroborate," Encyclopedia of
Reagents for Organic Synthesis,
John Wiley
& Sons, Ltd., 1995. 7.
W. J. Wechter, E. D. Murray, Jr., D. Kantoci, and M. E. Jung,
"Characterization of Two New Endogenous Natriuretic
Factors," Abstract, 29th
Annual Meeting, American Society of Neurology, November 1996. 8.
Crostic No. 49 in Crostics, No.
115, Simon & Schuster, New York, NY, ed. T. H. Middleton, 1996. 9.
S. E. Denmark, M. E. Jung, A. Pfaltz, B. Giese,
"Laudio for Professor
Doctor Albert Eschenmoser," Synlett 1999,
III. 10.
M. E. Jung, "Tungsten Hexachloride," Encyclopedia
of Reagents for Organic Synthesis,
John Wiley
& Sons, Ltd., 2006.
MEETING ABSTRACTS 1. Richardson, J. A.;
Amantea, C. M.;
Nguyen, K.; Jung, M. E.; Hahn, T. J.; Parhami, F. "Characterization of
osteogenic oxysterols and their molecular mechanism(s) of
action," J. Bone Mineral Res.
2005, 20, S414-S415 Suppl.
1. 2. Wechter, W. J.;
Murray, E. D.; Kantoci, D.; Jung, M. E. "Characterization of two new
endogenous natriuretic
factors," J. Am.
Soc. Nephrol. 1996, 7, A2867-A2867. 3. Anderson N. M.;
Marquez-Garban, D. C.; Deng, G.; Chen, H.-W.; Jung, M. E.; Pietras, R. J.
Proceedings of the American Association for the Advancement of Science,
Pacific Division 2012, 31 (Part 1), 103-104. "Development of a new approach
to kill non-small cell lung cancer with resistance to standard chemotherapy,"
[First Place Award in Health Sciences 2012].
SHORT COURSES 1. Nov. 1980:
Upjohn Co., Kalamazoo,
MI, "New Advances in the Use of Diels-Alder Reactions in
Synthesis." 2. Sept. 1985: American Cyanamid Co.,
Agricultural Research Division, Princeton, NJ, "Silicon in
Organic Synthesis." 3. Sept. 1987: Zhongshan University,
Guangzhou, PRC, "Modern Organic Synthesis." 4. Sept. 1987: Zhongshan University,
Guangzhou, PRC, "Silicon in Organic Synthesis." 5. April 1996:
3M, St. Paul, MN,
"Strategy and Design in Organic Synthesis." 6. April 1998: 3M, St. Paul, MN,
"New Methods in Heterocyclic Chemistry." 7. Dec. 1999:
Neurocrine
Biosciences, "Introduction to Modern Heterocyclic
Chemistry." 8. Mar. 2003:
Université
Pierre
et Marie Curie, Paris, "Modern Heterocyclic Chemistry."
9. May 2008:
Vertex, Inc., San Diego, "Modern Heterocyclic Chemistry."
10. Dec. 2011:
Université Pierre et Marie Curie, Paris, "Chimie Hétérocyclique (in French)."
PATENTS AND
APPLICATIONS
1. Cross, B.; Los, M.; Doehner, R. F., Jr.; Ladner, D. W.; Johnson, J. L.;
Jung, M. E.; Kamhi, V. M.; Tseng, S. S.; Finn, J. M.; Wepplo, P. J.
(Assignee: American Cyanamid Company) "Preparation of Novel Fused
Imidazolinylpyridines as Herbicides," Eur. Patent EP 227932 B1, (January 13, 1993) CAN 108:21884.
[pdf]
INVITED LECTURES AND POSTERS 681 Lectures, seminars, and presentations at international and
national chemical meetings and symposia, academic institutions, and industrial institutions from 1973-2024.
Graduate
- Columbia University
Aragon Pharmaceuticals, San Diego, CA, 2009 - 2013
Trius Pharmaceuticals, San Diego, CA, 2006 - 2013
Neurocrine Biosciences, Inc., La Jolla, CA, 2003 - 2009
OTHER PUBLICATIONS
2. Jung, M. E.; Gardiner, J. M. (Assignee: The Regents of the University of
California) "Process for the Synthesis of 2',3'-Dideoxynucleosides," US
Patent 5,220,003 (June 15, 1993).
[pdf]
3. Cross, B.; Los, M.; Doehner, R. F., Jr.; Ladner, D. W.; Johnson, J. L.;
Jung, M. E.; Kamhi, V. M.; Tseng, S. S.; Finn, J. M.; Wepplo, P. J.
(Assignee: American Cyanamid Company) "(2-Imidazolin-2-yl) Fused Heteropyridine
Compounds, Intermediates for the Preparation of and Use of Said Compounds as
Herbicidal Agents," US Patent 5,252,538 (October 12, 1993).
[pdf]
4. Harrington, P. E.; Jung, M. E. (Assignee: American Cyanamid Company) "Stereoselective
Bromination of β-Ribofuranosyl
Amide: Synthesis of Herbicidal Analogues of Hydantocidin," US Patent 5,354,868 (October 11, 1994).
[pdf]
5. Jung, M. E.; D'Amico, D. C. (Assignee: The Regents of the University of California) "Stereospecific
Synthesis of Aldols," US Patent 5,426,206 (June 20, 1995).
[pdf]
6. Harrington, P. E.; Jung, M. E. (Assignee: American Cyanamid Company) "Process and
Intermediates for the Preparation of (+)-Hydantocidin and Analogs Thereof," US Patent
5,543,510 (August 6, 1996).
[pdf]
7. Jung, M. E.; Cook, P. D.; Kawasaki, A. M. (Assignee: Isis Pharmaceuticals) "Method for
Removing Unreacted Electrophiles from a Reaction Mixture," US Patent 5,632,898 (May 27, 1997).
[pdf]
8. Fraser, A. S.; Manoharan, M.; Cook, P. D.; Jung, M. E.; Kawasaki, A. M. (Assignee: Isis
Pharmaceuticals) "Preparation of DNA having improved hybridization affinity and nuclease
resistance via alkylation of nucleosides with cyclic sulfates," US Patent 6,277,982
(August 21, 2001).
[pdf]
9. Manoharan, M.; Just, G.; Guzaev, A.; Roland, A.; Wang, J.; Jung, M. E. (Assignee: Isis Pharmaceuticals) "Solid
phase synthesis of alkylphosphonate-linked oligodeoxyribonucleotides," US Patent 6,486,313 (November 26, 2002).
[pdf]
10. Jung, M. E.; Xu, Y. (Assignee: The Regents of the University of California) "Synthesis of L-Ribose and
2-Deoxy-L-Ribose from D-Ribose," PCT Int. Appl. WO9839347, A2 19980911.
[pdf]
11. Manoharan, M.; Just, G.; Guzaev, A.; Roland, A.; Wang, J.; Jung, M. E. (Assignee:
Isis Pharmaceuticals) "Oligonucleotides having alkylphosphonate linkages and methods for
their preparation," US Patent 7,049,432 (May 23, 2006).
[pdf]
12. Morytko, M.; Zhang, Y.; Jung, M.; Finn, J. (Assignee: Cubist Pharmaceuticals)
"Lipopeptide stereoisomers, methods for preparing same, and useful intermediates," US Patent 7,262,268.
(August 28, 2007).
[pdf]
13. Morytko, M.; Zhang, Y.; Jung, M.; Finn, J. (Assignee: Cubist Pharmaceuticals)
"Lipopeptide stereoisomers, methods for preparing same, and useful intermediates," US Patent 7,335,726.
(February 26, 2008).
[pdf]
14. Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Welsbie, D.; Tran, C.; Wongvipat, J.;
Yoo, D. (Assignee: The Regents of the University of California) "Diarylhydantoin
Compounds," US Patent 7,709,517 (May 4, 2010). (Also 71 foreign patents/divisions issued for this work).
[pdf]
15. Jung, M. E.; Ouk, S.; Sawyers, C. L.; Chen, C. D.; Welsbie, D. (Assignee: The Regents
of the University of California) "Methods and Materials for Assessing Prostate Cancer
Therapies and Compounds," US Patent 7,718,684, (May 18, 2010). (Also 4 foreign patents/divisions issued for this work).
[pdf]
16. Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Welsbie, D.; Tran, C.; Wongvipat,
J.; Yoo, D. (Assignee: The Regents of the University of California) "Diarylhydantoin
Compounds," EP Patent 1,893,196. (January 18, 2012).
[pdf]
17. Jung, M. E.; Ouk, S.; Sawyers, C. L.; Chen, C. D.; Welsbie, D. (Assignee: The Regents
of the University of California) "Methods and Materials for Assessing Prostate Cancer
Therapies and Compounds," PCT Int. Appl. WO 2005099693 A2 20051027; NZ550102; AU2005232526 (A1).
[pdf]
18. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee:
Alnylam Pharmaceuticals) "Process for Desilylation of Oligonucleotides," US Patent 8,431,693,
(April 30, 2013).
[pdf]
19. Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M.
(Assignee: Cylene Pharmaceuticals) "Method for Converting Quinolone Esters into Quinolone
Amides," US Patent 7,652,134 (January 26, 2010).
[pdf]
20. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee: Alnylam
Pharmaceuticals) "Processes and Reagents for Desilylation of Oligonucleotides,"
US Patent 8,063,198 (November 22, 2011).
[pdf]
21. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee: Alnylam
Pharmaceuticals) "Processes and Reagents for Sulfurization of Oligonucleotides," US
Patent 8,058,448 (November 15, 2011).
[pdf]
22. Parhami, F.; Jung, M. E.; Dwyer, J. R.; Nguyen, K. (Assignee: The Regents of the
University of California) "Oxysterol Compounds and the Hedgehog Pathway," US Patent Appl.
20100034781 (February 11, 2010). (Also 4 foreign patents/divisions issued for this work).
[pdf]
23. Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee:
The Regents of the University of California) "Diarylthiohydantoin Compounds," US Patent 8,183,274 (May 22, 2012).
[pdf]
24. Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee: The Regents of
the University of California) "Treatment of Hyperproliferative Disorders with Diarylthiohydantoin Compounds,"
US Patent 9,126,941 (September 8, 2015).
[pdf]
25. Parhami, F.; Jung, M. E.; Dwyer, J. R.; Nguyen, K. (Assignee: The Regents of the
University of California) "Oxysterol Compounds and the Hedgehog Pathway," PCT Int. Appl.
WO 2007098281 A2 20070830.
[pdf]
26. Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C.; Wongvipat, J. "Diarylhydantoin Compounds as Androgen Receptor
Modulators," (Assignee: The Regents of the University of California) US Patent 8,110,594
(February 7, 2012). (Also 24 foreign patents/divisions issued for this work.)
[pdf]
27. Jung, M. E.; Yoo, D. (Assignee: The Regents of the University of California) "Diarylthiohydantoin
Compounds," US Patent 8,680,291 (March 25, 2014). (Also 11 foreign patents/divisions issued for this work).
[pdf]
28. Jung, M. E.; Sawyers, C. L.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee: The Regents of the
University of California) "Androgen Receptor Modulators for the Treatment of Prostate Cancer and
Androgen Receptor-Associated Diseases," US Patent 8,445,507 (May 21, 2013). (Also 41 foreign
patents/divisions issued for this work).
[pdf]
29. Jung, M. E.; Sawyers, C. L.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee: The Regents
of the University of California) "Androgen Receptor Modulator for the Treatment of
Prostate Cancer and Androgen Receptor-Associated Diseases," EP Patent 2,368,550.
(September 4, 2013).
[pdf]
30. Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C.; Wongvipat, J. "Diarylhydantoin Compounds as Androgen Receptor
Modulators," (Assignee: The Regents of the University of California) US Patent 8,648,105
(February 11, 2014).
[pdf]
31. Jung, M. E.; Sawyers, C. L.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee: The Regents of the
University of California) "Androgen Receptor Modulators for the Treatment of Prostate Cancer and
Androgen Receptor-Associated Diseases," US Patent 8,802,689 (August 12, 2014). (Also 142 foreign
patents/divisions issued for this work).
[pdf]
32. Jung, M. E.; Sawyers, C. L.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee: The Regents of the
University of California) "Androgen Receptor Modulators for the Treatment of Prostate Cancer and
Androgen Receptor-Associated Diseases," US Patent 9,388,159 (July 12, 2016).
[pdf]
33. Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C.; Wongvipat, J. "Diarylhydantoin Compounds as Androgen
Receptor Modulators," (Assignee: The Regents of the University of California) US Patent 8,110,594
(February 7, 2012).
[pdf]
34. Parhami, F.; Jung, M. E.; Nguyen, K.; Yoo, D.; Kim, W.-K. (Assignee: The Regents of
the University of California) "Oxysterols for Activation of Hedgehog Signaling,
Osteoinduction, Antiadipogenesis, and Wnt Signaling," US Patent 9,526,737 (December 27, 2016).
(Also 2 foreign patents/divisions issued for this work).
[pdf]
35. Lee, B; Jung, M. E.; Wolf, M. C.; Zhang, T. (Assignee: The Regents of the University
of California) "Novel Antiviral Agents for Enveloped Viruses," PCT Int. Appl. WO
2010044924 A1 20100422.
[pdf]
36. Schiestl, R. H.; Rivina, Y. O.; Jung, M. E.; Damoiseaux, R. (Assignee: The Regents of the University
of California) "Compounds and compositions for mitigating Radiation-Induced Tissue Damage
and Lethality," US Patent 9,045,474 (June 2, 2015).
[pdf]
37. Manoharan, M.; Rajeev, K. G.; Jayaraman, M.; Butler, D.; Jung, M. E. (Assignee:
Tekmira Pharmaceuticals Corporation) "Lipid compositions," US Patent 8,883,202 (November 11, 2014). (Also 22 foreign patents/divisions issued for this work)
[pdf]
38. Parhami, F.; Kim, W.-K.; Jung, M. E.; Nguyen, K. (Assignee: The Regents of the
University of California) "Inhibition of PPAR gamma expression by specific osteogenic oxysterols,"
US Patent 8,022,052 (September 20, 2011).
[pdf]
39. Parhami, F.; Kim, W.-K.; Jung, M. E.; Nguyen, K. (Assignee: The Regents of the University of California)
"Inhibition of peroxisome proliferator activated receptor gamma expression by specific osteogenic oxysterols,"
PCT Int. Appl. WO 2011006087 .
[pdf]
40. Jung, M. E.; Clubb, R. T.; Yi, S. W.; Suree, N.; Clemens, J. J. (Assignee: The Regents
of the University of California) "Preparation of pyridazin-3-one Derivatives as Sortase A Inhibitors,"
PCT Int. Appl. WO 2011028492 A2 20110310; US Patent Appl. 2012/149710 (A1).
[pdf]
41. Manoharan, M.; Jayaprakash, N. K.; Rajeev, K. G.; Jung, M. E. (Assignee: Alnylam
Pharmaceuticals) "Monomers and oligonucleotides comprising cycloaddition adducts," US Patent 9,566,340
(February 14, 2017).
[pdf]
42. Parhami, F.; Jung, M. E.; Nguyen, K. T.; Matsui, W.; Yoo, D.; Meliton, V. (Assignee:
The Regents of the University of California) "Oxysterols that activate liver X receptor
signaling and inhibit hedgehog signaling," PCT Int. Appl. WO 2011103175 A2; US Patent Appl. 2016/206631 (A1).
[pdf]
43. Lee, B; Jung, M. E.; Lee, J.; Vigant, F.; Bradley, P.; Wolf, M. C.; Hajagos, B. E.
(Assignee: The Regents of the University of California) "Broad Spectrum Antiviral and
Antiparasitic Agents," US Patent 9,139,575 (September 22, 2015).
[pdf]
44. Chen, Z.; Creighton, C. J.; Cunningham, M.; Finn, J.; Hilgers, M.; Jung, M. E.;
Kohnen, L. A.; Lam, T.; Li, X.; Stidham, M.; Tari, L.; Trzoss, M.; Zhang, J. (Assignee:
Trius Therapeutics, Inc.) "Dihydrofolate Reductase Inhibitors," US Patent 8,835,445
(September 16, 2014).
[pdf]
45. Manoharan, M.; Rajeev, K. G.; Jayaraman, M.; Jung, M. E. (Assignee: Tekmira Pharmaceuticals
Corporation) "Methods and compositions for delivery of active agents," PCT Int. Appl. WO 2012016184
A2 20120202; US Patent Appl. 2016/250354 (A1).
[pdf]
46. Gatti, R. A.; Du, L.; Damoiseuax, R.; Lai, C.-H.; Jung, M. E.; Ku, J.-M.;
Bertoni, C. (Assignee: The Regents of the University of California)
"Premature-termination-codons readthrough compounds," US Patent 9,255,088 (February 9, 2016)
[pdf]
47. Bensen, D.; Chen, Z.; Finn, J.; Lam, T. T.; Lee, S. J.; Li, X.; Phillipson, D. W.;
Tari, L. W.; Trzoss, M.; Zhang, J.; Lightstone, F. C.; Nguyen, T. B.; Wong, S. E.;
Aristoff, P.; Jung, M. E. (Assignee: Trius Therapeutics, Inc.) "Tricyclic Gyrase Inhibitors,"
US Patent 9,732,083. (August 15, 2017)
[pdf]
48. Gatti, R. A.; Du, L.; Hu, H.; Damoiseuax, R.; Jung, M. E.; Ku, J.-M.; Completo, G.
(Assignee: The Regents of the University of California) "Premature-termination-codons
readthrough compounds," PCT Int. Appl. WO 2013142346 A1 20130926.
[pdf]
49. Pietras, R. J.; Jung, M. E.; Marquez-Garban, D. C.; Deng, G. (Assignee: The Regents
of the University of California) "Compositions and methods for treating cancer," US Patent 9,266,901 (February 23, 2016).
[pdf]
50. Parhami, F.; Jung, M. E.; Stappenbeck, F.; Pierce, W. M.; Taylor, K. G.; Merten, K. E.
(Assignee: The Regents of the University of California) "Novel oxysterol analogue, Oxy149,
induces osteogenesis and hedgehog signaling and inhibits adipogenesis," PCT Int. Appl.
WO 2013169397 A1 20131114.
[pdf]
51. Witte, O.; Clark, P. M.; Castillo, B. G. F.; Jung, M. E.; Evdokimov, N. M (Assignee:
The Regents of the University of California) "A positron emission tomography probe to monitor
selected sugar metabolism in vivo," US Patent 9,592,309. (March 14, 2017)
[pdf]
52. Parhami, F.; Jung, M. E.; Stappenbeck, F. (Assignee: The Regents of the University of
California) "Oxysterol analogue Oxy133 induces osteogenesis and hedgehog signaling and inhibits
adipogenesis," US Patent 9,717,742. (August 1, 2017). (Also 24 patents/divisions issued from this work.)
[pdf]
53. Pietras, R. J.; Jung, M. E.; Marquez-Garban, D. C.; Deng, G. (Assignee: The Regents of the
University of California) "Compounds and Methods of Treating Cancer," US Patent 9,862,693.
(January 9, 2018).
[pdf]
54. Bensen, D.; Borchardt, A.; Chen, Z.; Finn, J. M.; Lam, T. T.; Lee, S. J.; Li, X.; Tari, L. W.;
Teng, M.; Trzoss, M.; Zhang, J.; Jung, M. E.; Lightstone, F. C.; Wong, S. E.; Nguyen, T. B.
(Assignee: Trius Therapeutics, Inc.) "Tricyclic Gyrase Inhibitors," PCT Int. Appl. (2014),
WO 2014043272 A1 20140320; US Patent Appl. 2015/0246934. (September 3, 2015)
[pdf]
55. Gillespie, E.; Damoiseaux, R.; Ho, C.-L. C.; Chamberlain, B. T.; Jung, M. E.; Bradley, K. A.
(Assignee: The Regents of the University of California) "Protective molecules against anthrax
toxin," PCT Int. Appl. (2014), WO 2014113607 A1 20140724.
56. Pietras, R. J.; Jung, M. E. (Assignee: The Regents of the University of California)
"Methods of Using Estrogen Receptor-β
Ligands as Radiation Mitigators," US Pat. Appl. Publ. (2015), US 20150018398 A1.
57. Radu, C. G.; Li, Z.; Gipson, R. M.; Wang, J.; Satyamurthy, N.; Lavie, A.; Murphy, J. M.;
Nathanson, D. A.; Jung, M. E. (Assignee: The Regents of the University of California)
"Deoxycytidine Kinase Inhibitors," US Patent 9,598,404 (March 21, 2017).
[pdf]
58. Pietras, R. J.; Jung, M. E.; Marquez-Garban, D. C.; Deng, G. (Assignee: The Regents
of the University of California) "Compositions and Methods for Treating Cancer,"
US Patent 9,512,138 (December 6, 2016).
[pdf]
59. Huang, J.; Chin, R.; Diep, S.; Pai, M. Y.; Lomenick, B. E.; Fu, X.; Reue, K.; Vergnes, L.;
Jung, M. E.; Deng, G.; et al (Assignee: The Regents of the University of California) "Compositions
and Methods for Treating Aging and Age-related Diseases and Symptoms,"
PCT Int. Appl. (2015), WO 2015123229 A1 20150820; US Patent Appl. 2016/354334 A1.
60. Jagodzinska, B.; Campagna, J.; Pham, J.; Jung, M. E.; John, V.; Rao, R.; Bredesen, D. E. (Assignee:
The Regents of the University of California), "Preparation of alaproclate and analogs as ApoE4-targeted
therapeutics that increase SirT1," PCT Int. Appl. (2016), WO 2016028910 A1 20160225.
61. Pietras, R. J.; Jung, M. E.; Marquez-Garban, D. C.; Deng, G. (Assignee: The Regents of the University
of California) "Preparation of 11β-Aryloxy Estradiols
as Estrogen Receptor Modulators," PCT Int. Appl. (2016), WO 2016085825 A1 20160602.
62. Campbell, D.; Jung, M. E. (Assignee: Enlibrium, Inc.) "Imidocarbonimidic Diamide Analogs," US Prov.
Patent Appl. No. 62/345,708 (2016) (June 3, 2016).
63. Parhami, F.; Jung, M. E.; Stappenbeck, F. (Assignee: The Regents of the University of California)
"Oxysterol analogue Oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis," US
Pat. Appl. Publ. (2015), US 20150118277 A1. (Apri 30, 2015). [pdf]
64. Manoharan, M.; Rajeev, K. G.; Jayaraman, M.; Jung, M. E. (Assignee: Alnylam Pharmaceuticals)
"Methods and compositions for delivery of active agents," US Pat. Appl. Publ. (2013), US 20130323269
A1. (December 5, 2013). [pdf]
65. Witte, O.; Clark, P. M.; Castillo, B. G. F.; Jung, M. E.; Evdokimov, N. M (Assignee: The Regents of the
University of California) "A positron emission tomography probe to monitor selected sugar metabolism in vivo,"
US Patent 9,592,309 B2 (March 14, 2017). [pdf]
66. Parhami, F.; Jung, M. E.; Stappenbeck, F.; Pierce, W.; Taylor, K. G.; Merten, K. E. (Assignee: The
Regents of the University of California) "Novel oxysterol analogue, Oxy149, induces osteogenesis and
hedgehog signaling and inhibits adipogenesis," US Pat. Appl. Publ. (2015), US 20150140059 A1. (May 21, 2015).
[pdf] (Also 11 foreign patents/divisions issued for this work).
67. Gatti, R. A.; Du, L.; Hu, H.; Damoiseuax, R.; Jung, M. E.; Ku, J.-M.; Completo, G. (Assignee: The Regents
of the University of California) "Premature-termination-codons readthrough compounds," US Patent 9,598,395
(March 21, 2017). [pdf]
68. Jung, M. E.; Clubb, R. T.; Yi, S. W.; Suree, N.; Clemens, J. J. (Assignee: The Regents of the University
of California) "Sortase A Inhibitors," US Pat. Appl. Publ. (2012), US 20120149710 A1 20120614. (JUne 14, 2012).
[pdf]
69. Manoharan, M.; Nair, J. K.; Rajeev, K. G.; Jung, M. E. (Assignee: Alnylam Pharmaceuticals)
"Monomers and oligonucleotides comprising cycloaddition adduct(s)," US 9,198,972.
(December 1, 2015). [pdf]
70. Manoharan, M.; Rajeev, K. G.; Jayaraman, M.; Butler, D.; Jung, M. E. (Assignee: Arbutus Biopharma Corporation)
"Liquid compositions," US Patent 9,694,077 B2. (July 4, 2017). [pdf]
71. Lee, B; Jung, M. E.; Wolf, M. C.; Zhang, T. (Assignee: The Regents of the University of California)
"Novel Antiviral Agents for Enveloped Viruses," US Pat. Appl. Publ. (2012), US 20120219613 A1 20120830. (August 30, 2012).
[pdf]
72. Krogstad, P.; Jung, M. E.; Zuo, J.; Xing, Y. (Assignee: The Regents of the University of California)
"Potent antiviral pyrazolopyridine compounds," US Patent 11,059,817. (July 13, 2021).
[pdf]
73. Pietras, R. J.; Jung, M. E.; Marquez-Garban, D. C.; Deng, G. (Assignee: The Regents of the University of California)
"Compositions and Methods for Treating Cancer," PCT Int. Appl. (2017), WO 2017059102A1 20170406. (April 6, 2017).
[pdf]
74. Manoharan, M.; Nair, J. K.; Rajeev, K. G.; Jung, M. E. (Assignee: Alnylam Pharmaceuticals) "Monomers
and Oligonucleotides comprising cycloaddition adducts," US Patent 10,550,386 B2. (February 4, 2020).
[pdf]
75. Parhami; F.; Stappenbeck, F.; Jung, M. E.; Pierce, Jr., W. M.; Merten, K.; Taylor, K. G.
(Assignee: The Regents of the University of California and the University of Louisville Research Foundation)
"Bone-selective osteogenic oxysterol-bone targeting agents," US Patent 9,683,009 (June 20, 2017).
[pdf]
76. Gera, J. F.; Lichtenstein, A.; Jung, M. E.; Lee, J.; Holmes, B.; Benavides-Serrato, A. (Assignee: The Regents of the
University of California) "Preparation of phenylmethyl-pyrroledione derivatives and analogues for use as IRES-mediated
protein synthesis inhibitors," PCT Int. Appl. (2017), WO 2017192665 A1 20171109 (November 9, 2017).
[pdf]
77. Pietras, R. J.; Jung, M. E.; Marquez-Garban, D. C.; Deng, G. (Assignee: The Regents of the University of California)
"Compositions and Methods for Treating Hyperproliferative Diseases including Cancer," PCT Int. Appl. (2017) WO 2017059102
A1 (April 6, 2017). [pdf]
78. Chute, J. P.; Jung, M. E.; E. Diers (Assignee: The Regents of the University of California)
"β-Aminocarbonyl derivatives
and related compounds for hematopoietic regeneration and their preparation," PCT Int. Appl.
(2017) WO 2017205795 A1 20171130 (November 30, 2017).[pdf]
79. Pietras, R. J.; Jung, M. E. (Assignee: The Regents of the University of California) "Synthesis of Estrogen Receptor
Modulators," PCT Int. Appl. (2017), WO 2017205611 A1 20171130 (November 30, 2017).
[pdf]
80. Campbell, D.; Jung, M. E. (Assignee: Enlibrium, Inc.) "Imidocarbonimidic Diamide Analogs," PCT WO 2017210580 A1
(December 7, 2017). [pdf]
81. Jung, M. E.; Voskuhl, R. (Assignee: The Regents of the University of California)
"Estrogen Receptor Ligands, Compositions and Methods Related Thereto," US Patent 10,980,767 B2. (April 20, 2021).
[pdf]
82. Lichtenstein, A.; Jung, M. E.; Gera, J. F.; Lee, J.; Shi, Y. (Assignee: The Regents of the University of California)
"Inhibitors of mTOR-DEPTOR Interaction and Methods of Use Thereof," PCT WO 2018085753 A1 20180511
(May 11, 2018). [pdf]
83. Pietras, R. J.; Jung, M. E. (Assignee: The Regents of the University of California)
"Estrogen Receptor Inhibitors and Uses Thereof," US Patent Appl. 62/681,423
(June 8, 2018). [pdf]
84. Rettig, M.; Jung, M. E.; Ralalage, D. E. N. G.; An, J. (Assignee: The Regents of the University of California and the
US Government represented by the Department of Veterans Affairs)
"Inhibitors of the N-terminal domain of the androgen receptor," US Patent 11,261.152 B2 (March 1, 2022).
[pdf]
85. Gera, J. F.; Lichtenstein, A.; Jung, M. E.; Lee, J.; Holmes, B.; Benavides-Serrato,
A. (Assignee: The Regents of the University of California) "Preparation of dihydrothiazolyl
ureas, thioureas, amides and carbamates as inhibitors of mTOR-Rictor interactions,"
PCT Int. Appl. (2018), WO2018187414 A1 20181011 (October 11, 2018).
[pdf]
86. Lowry, W. E.; Jung, M. E.; Christofk, H. R.; Liu, X.; FLores, A. (Assignee: The Regents of the University of California)
"Compositions and methods for modulating hair growth," US Patent 11,312,714 (April 26, 2022).
[pdf]
87. Nathanson, D. A.; Jung, M. E.; Tsang, J.; Urner, L.; Clark, P. M.; Cloughesy, T. F.
(Assignee: The Regents of the University of California) "Compositions and methods for
treating cancer," US Provisional Appl. (2019), 62/819,322 (March 15, 2019).
[pdf]
88. Nathanson, D. A.; Mai, W. X.; Jung, M. E.; Clark, P. M.; Cloughesy, T. F.; Kim, G.; Tsang, J.; Urner, L.
(Assignee: The Regents of the University of California) "Preparation of acyl aminoquinazolines and
compositions containing them for treating cancer," PCT Int. Appl. (2019), WO 2019067543 A1 20190404 (April 4, 2019).
[pdf]
89. Krogstad, P.; Jung, M. E.; Zao, J.; Xing, Y. (Assignee: The Regents of the University of California)
"Potent antiviral pyridine-containing compounds and therapeutic uses thereof for treating viral infections,"
US Patent 11,180,498 (November 23, 2021).
[pdf]
90. Krogstad, P.; Jung, M. E.; Zao, J.; Xing, Y. (Assignee: The Regents of the University of California)
"Potent antiviral pyridine-containing compounds and therapeutic uses thereof for treating viral infections,"
EP Patent 3,687,529 (July 12, 2023). [pdf]
91. Chute, J. P.; Jung, M. E.; Diers, E.; Gim, H. J. (Assignee: The Regents of the University of California)
"Compounds and methods for hematopoietic regeneration," PCT Int. Appl. (2019), WO 2019108800 (June 6, 2019).
[pdf]
92. Murphy, J. M.; Jung, M. E.; Pietras, R. J.; Comin-Anduix, B.; Marquez-Garban, D. C. (Assignee: The
Regents of the University of California) "Biguanide compositions and methods related thereto,"
PCT Int. Appl. (2019), WO 2019108788 (June 6, 2019). [pdf]
93. Jung, M. E.; Chen, X.; Wang, C.-Y.; Li, J.; Zheng, J. (Assignee: The Regents of the University of California)
"Inhibitors of the Wnt/beta catenin pathway" US Patent 11,708,329 (July 25, 2023).
[pdf]
94. Pietras, R. J.; Jung, M. E. (Assignee: The Regents of the University of California)
"Estrogen Receptor Inhibitors and Uses Thereof," PCT Int. Appl. (2019), WO2019236901 A1 20191212
(December 12, 2019). [pdf]
95. Iliopoulos, D.; Jung, M. E.; Kim, J.; Hoffman, J. M.; Karagiannides, I. (Assignee: The Regents of the University of California)
"Compositions and methods for treating epigenetic disease," US Patent 11,952,362 B2
(April 9, 2024). [pdf]
96. Jung, M. E.; Huang, J.; Xing, Y.; Lomenick, B. E.; Chai, M.; Fu, X. (Assignee:
The Regents of the University of California) "Preparation of prodrugs of alpha-ketoglutarate,
alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof," US Patent 11,524,948 A120221213
(December 13, 2022). [pdf]
97. Lowry, W. E.; Jung, M. E.; Christofk, H. R.; Liu, X. (Assignee: The Regents of the University of California)
"Preparation of indolyl acrylates and related compounds alone and in compositions and methods for modulating hair growth,"
PCT Int. Appl. (2020), WO 2020142413 A1 20200709 (July 7, 2020). [pdf]
98. Radu, C. G.; Jung, M. E.; Sun, D.; Satyamurthy, N.; Van Valkenburgh, J.; Pan, R.; Poddar, S. (Assignee: The Regents
of the University of California) "Preparation of thiosemicarbazone compounds and uses thereof," PCT Int. Appl. (2020),
WO 2020176349 A1 20200903 (September 3, 2020). [pdf]
99. Nathanson, D. A.; Jung, M. E.; Tsang, J.; Urner, L.; Clark, P. M.; Cloughesy, T. F.; Kim, G. (Assignee: The Regents
of the University of California) "Preparation of quinazoline derivatives, their compositions and methods for treating
cancer," PCT Int. Appl. (2020), WO 2020190765 A2 20200924 (September 24, 2020).
[pdf]
100. Rettig, M.; Jung, M. E.; Ralalage, D. E. N. G.; An, J. (Assignee: The Regents of the University of California and
the US Government represented by the Department of Veterans Affairs) "Acrylamide derivatives and related compounds as
inhibitors of the N-terminal domain of the androgen receptor and their preparation," PCT Int. Appl. (2020), WO
2020205470 A120201008 (October 8, 2020). [pdf]
101. John, V.; Jagodzinska, B.; Spilman, P.; Campagna, J.; Vadivel, K.; Jung, M. E. (Assignee: The Regents of the
University of California) "Compositions comprising allosteric inhibitors of beta-secretase (BACE) for the treatment of
neurological diseases and disorders," PCT Int. Appl. (2020), WO 2020232056 A120201119 (November 19, 2020).
[pdf]
102. Lowry, W.; Novitch, B.; Jung, M. E.; Liu, X.; Samarasinghe, R.; Korsakova, E. (Assignee: The Regents of the
University of California) "Pifithrin analogues and methods of treating rett syndrome," PCT Int. Appl. (2020), WO
2020247336 20201210 (December 10, 2020). [pdf]
103. Manoharan, M.; Rajeev, K. G.; Jayaraman, M.; Butler, D.; Jung, M. E. (Assignee: Arbutus Biopharma Corporation)
"Liquid compositions," US 10,456,473. (October 29, 2019). [pdf]
104. Roos, M.; Jung, M. E.; Gim, H. J. (Assignee: The Regents of the University of California) "Inhibitors of lin28
and methods of use thereof," PCT Int. Appl. (2021), WO 2021126779 A1 20210624 (June 24, 2021).
[pdf]
105. Jung, M. E.; Liu, X. (Assignee: The Regents of the University of California) "Synthesis
of compounds to promote hair growth," PCT Int. Appl. (2021), WO 2021127482 A1 20210624 (June 24, 2021).
[pdf]
106. Sun, D. L.; Jung, M. E.; Gil, D. W.; Lowry, W. E.; Christofk, H. R.; Flores, A. A.; Liu, X. (Assignees:
The Regents of the University of California and Pelage Pharmaceuticals) "Preparation of pyrrolopyridines useful
alone or in compositions for modulating hair growth," PCT Int. Appl. (2022), WO 2022006039 A1 20220106
(January 6, 2022). [pdf]
107. Sun, D. L.; Jung, M. E.; Gil, D. W. (Assignees: The Regents of the University of California and Pelage Pharmaceuticals)
"Preparation of pyrrolopyridines useful alone or in compositions for modulating hair growth," PCT Int. Appl. (2022), WO 2022006040 A1 20220106
(January 6, 2022). [pdf]
108. Deb, A.; Jung, M. E.; Chen, X.; Li, S.; Xing, Y.; Ding, H. (Assignees: The Regents of the University of California) "Small
molecule inhibitors of ENPP1," PCT Int. Appl. (2022), WO 2022056068 A1 20220317 (March 17, 2022).
[pdf]
109. Nathanson, D. A.; Jung, M. E.; Cloughesy, T. F.; Urner, L.; Clark, P. M.; Tsang, J. (Assignees: The Regents of the University
of California) "Compositions and methods for treating cancer," PCT Int. Appl. (2022), WO 2022061201 A1 20220324 (March 24, 2022).
[pdf]
110. Vernier, J.-M.; Nathanson, D. A.; Jung, M. E.; Cloughesy, T. F.; Urner, L.; Clark, P. M.; Tsang, J. (Assignees: The Regents
of the University of California and Erasca Inc.) "Compositions and methods for treating cancer," PCT Int. Appl. (2022),
WO 2022061202 A1 20220324 (March 24, 2022). [pdf]
111. Campagna, J.; John, V.; Jung, M. E. (Assignee: The Regents of the University of California) "Compositions and methods for treating
neurodegenerative diseases and disorders," PCT Int. Appl. (2022), WO 2022076507 A1 20220414 (April 14, 2022).
[pdf]
112. Geschwind, D. H.; Jung, M. E.; Deng, L.; Hinz, F.; Murphy, J. M.; Ma, G.; Damoiseaux, R. (Assignee: The Regents of the University of California)
"Preparation of N-substituted benzo[d]-isothiazol-3-amines for treating tauopathies,"
PCT Int. Appl. (2022), 2022178283 A1 20220825 (August 25, 2022).
[pdf]
113. Jung, M. E.; Shrestha, B.; Wang, C.-Y.; Zhou, P. (Assignee: The Regents of the University of California)
"Compounds and Methods for Inhibiting DNA damage responses," US Provisional Patent Application no. 63/436,316 (December 30, 2022).
114. Jung, M. E.; Voskuhl, R. (Assignee: The Regents of the University of California) "Estrogen Receptor Ligands, Compositions and
Methods Related Thereto," US Patent 11,622,954 B2 (April 11, 2023).
[pdf]
115. Deb, A.; Jung, M. E.; Chen, X.; Li, S.; Xing, Y.; Ding, H. (Assignees: The Regents of the University of California)
"Small molecule inhibitors of ENPP1," PCT Int. Appl. (2023), WO 2023168240 A1 20230907 (September 7, 2023)
[pdf]
116. Pietras, R. J.; Jung, M. E. (Assignee: The Regents of the University of California)
"Estrogen Receptor Modulators and Combinations" CA Patent 3,063,834 (February 22, 2024).
[pdf]
117. Ding, H..; Jung, M. E.; Pajonk, F.; He, L.; Chen, X. (Assignee: The Regents of the University of California)
"Compounds and methods for treating cancer," PCT Int. Appl. (2024), WO 2024091450 A1 20240502 (May 2, 2024).
[pdf]
118. Wang, C.-Y..; Zhou, P.; Jung, M. E.; Shrestha, B. (Assignee: The Regents of the University of California)
"Compounds and methods for treating cancer," PCT Int. Appl. (2024), WO 2024145585 A1 20240704 (July 4, 2024).
[pdf]
Summary: 60 issued patents; 58 patent applications (56 pending). An additional 324 foreign
patents have been issued for some of the issued patents.